ACADIA Pharmaceuticals

Secular Trends And Pipeline Expansion Will Drive CNS Therapy Adoption

AnalystHighTarget

Not Invested

Consensus Narrative from 19 Analysts

Published

03 May 25

Updated

15 Aug 25

AnalystHighTarget's Fair Value

US$40.00

36.7% undervalued

15 Aug

US$25.33

64.5%

3.0%

Author's Valuation

US$40.0

36.7% undervalued

AnalystHighTarget Fair Value

Narrative

Updates1

Shared on07 May 25
Fair value Increased 2.56%

AnalystHighTarget Fair Value

US$40.0

36.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

10.87%

Biotech revenue growth rate

13.11%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$614.75m

Earnings '28

14.02x

PE Ratio '28

US$8.62b

Market Cap '28

US$8.62b

Market Cap '28

177.51m

No. shares '28

US$48.55

Share Price '28

US$48.55 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$39.88

Fair Value '25

Secular Trends And Pipeline Expansion Will Drive CNS Therapy Adoption

Shared on07 May 25Fair value Increased 2.56%

Shared on07 May 25
Fair value Increased 2.56%